Magle Chemoswed Holding AB

Equities

MAGLE

SE0014401014

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:24:00 2024-05-10 am EDT 5-day change 1st Jan Change
32 SEK 0.00% Intraday chart for Magle Chemoswed Holding AB 0.00% +26.98%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023 CI
Magle Chemoswed Holding AB (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million. CI
Magle Chemoswed Holding AB Proposes Dividend for the Fiscal Year 2023 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Magle Group Enters Collaboration with Sirtex Medical to Support the International Commercialization of Embocept S Dsm 50 Um CI
Magle Chemoswed Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Magle Group Announces Positive Results from Post-Market Clinical Follow-Up of SmartPAN CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait CI
Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina CI
Magle Chemoswed Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Magle Appoints New Chief Marketing/Innovation Officer MT
Magle Group Appoints Helena Ossmer Thedius as New Chief Marketing and Innovation Officer CI
Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding CI
Magle Chemoswed Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN® CI
Magle Chemoswed Holding AB Announces Post Market Clinical Study for SmartPAN® CI
Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Magle Chemoswed Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 CI
Chart Magle Chemoswed Holding AB
More charts
Magle Chemoswed Holding AB is a Sweden-based company that conducts research, development and manufacturing in the fields of pharmaceutical chemistry and pharmaceutical technology. The Company's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
  1. Stock Market
  2. Equities
  3. MAGLE Stock
  4. News Magle Chemoswed Holding AB
  5. Magle Appoints New Chief Marketing/Innovation Officer
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW